PMC:7652766 / 84718-85592 JSONTXT

{"project":"LitCovid-PD-HP","denotations":[{"id":"T125","span":{"begin":862,"end":873},"obj":"Phenotype"}],"attributes":[{"id":"A125","pred":"hp_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/HP_0001888"}],"text":"In a case study conducted by Monneret et al. (301), compassionate administration of IL-7 to a patient with severe COVID-19 significantly improved total lymphocyte count and HLA-DR expression in circulating monocytes four days after administration of the first dose. The patient also showed a significant improvement in lung involvement and negative viral load. Another study conducted by Laterre et al. (302), who administered IL-7 to COVID-19 patients found that there was a significant improvement in the lymphocyte count after starting treatment, in addition, the patients did not show any change in TNF-α levels, IL-1β, and IL-12p70, which may indicate that IL-7 therapy may be safe for patients with severe inflammatory changes. Thus, the use of IL-7-based immunotherapy can be an important tool to be used in future clinical trials in patients with severe lymphopenia."}

{"project":"LitCovid-sentences","denotations":[{"id":"T413","span":{"begin":0,"end":265},"obj":"Sentence"},{"id":"T414","span":{"begin":266,"end":360},"obj":"Sentence"},{"id":"T415","span":{"begin":361,"end":733},"obj":"Sentence"},{"id":"T416","span":{"begin":734,"end":874},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In a case study conducted by Monneret et al. (301), compassionate administration of IL-7 to a patient with severe COVID-19 significantly improved total lymphocyte count and HLA-DR expression in circulating monocytes four days after administration of the first dose. The patient also showed a significant improvement in lung involvement and negative viral load. Another study conducted by Laterre et al. (302), who administered IL-7 to COVID-19 patients found that there was a significant improvement in the lymphocyte count after starting treatment, in addition, the patients did not show any change in TNF-α levels, IL-1β, and IL-12p70, which may indicate that IL-7 therapy may be safe for patients with severe inflammatory changes. Thus, the use of IL-7-based immunotherapy can be an important tool to be used in future clinical trials in patients with severe lymphopenia."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3085","span":{"begin":84,"end":88},"obj":"Gene"},{"id":"3086","span":{"begin":427,"end":431},"obj":"Gene"},{"id":"3087","span":{"begin":603,"end":608},"obj":"Gene"},{"id":"3088","span":{"begin":617,"end":622},"obj":"Gene"},{"id":"3089","span":{"begin":662,"end":666},"obj":"Gene"},{"id":"3090","span":{"begin":751,"end":755},"obj":"Gene"},{"id":"3091","span":{"begin":432,"end":434},"obj":"Gene"},{"id":"3092","span":{"begin":89,"end":91},"obj":"Gene"},{"id":"3093","span":{"begin":94,"end":101},"obj":"Species"},{"id":"3094","span":{"begin":270,"end":277},"obj":"Species"},{"id":"3095","span":{"begin":444,"end":452},"obj":"Species"},{"id":"3096","span":{"begin":567,"end":575},"obj":"Species"},{"id":"3097","span":{"begin":691,"end":699},"obj":"Species"},{"id":"3098","span":{"begin":841,"end":849},"obj":"Species"},{"id":"3099","span":{"begin":474,"end":475},"obj":"Gene"},{"id":"3100","span":{"begin":290,"end":291},"obj":"Gene"},{"id":"3101","span":{"begin":92,"end":93},"obj":"Gene"},{"id":"3102","span":{"begin":3,"end":4},"obj":"Gene"},{"id":"3103","span":{"begin":114,"end":122},"obj":"Disease"},{"id":"3104","span":{"begin":435,"end":443},"obj":"Disease"},{"id":"3105","span":{"begin":862,"end":873},"obj":"Disease"}],"attributes":[{"id":"A3085","pred":"tao:has_database_id","subj":"3085","obj":"Gene:3574"},{"id":"A3086","pred":"tao:has_database_id","subj":"3086","obj":"Gene:3574"},{"id":"A3087","pred":"tao:has_database_id","subj":"3087","obj":"Gene:7124"},{"id":"A3088","pred":"tao:has_database_id","subj":"3088","obj":"Gene:3552"},{"id":"A3089","pred":"tao:has_database_id","subj":"3089","obj":"Gene:3574"},{"id":"A3090","pred":"tao:has_database_id","subj":"3090","obj":"Gene:3574"},{"id":"A3091","pred":"tao:has_database_id","subj":"3091","obj":"Gene:6999"},{"id":"A3092","pred":"tao:has_database_id","subj":"3092","obj":"Gene:6999"},{"id":"A3093","pred":"tao:has_database_id","subj":"3093","obj":"Tax:9606"},{"id":"A3094","pred":"tao:has_database_id","subj":"3094","obj":"Tax:9606"},{"id":"A3095","pred":"tao:has_database_id","subj":"3095","obj":"Tax:9606"},{"id":"A3096","pred":"tao:has_database_id","subj":"3096","obj":"Tax:9606"},{"id":"A3097","pred":"tao:has_database_id","subj":"3097","obj":"Tax:9606"},{"id":"A3098","pred":"tao:has_database_id","subj":"3098","obj":"Tax:9606"},{"id":"A3099","pred":"tao:has_database_id","subj":"3099","obj":"Gene:351"},{"id":"A3100","pred":"tao:has_database_id","subj":"3100","obj":"Gene:351"},{"id":"A3101","pred":"tao:has_database_id","subj":"3101","obj":"Gene:351"},{"id":"A3102","pred":"tao:has_database_id","subj":"3102","obj":"Gene:351"},{"id":"A3103","pred":"tao:has_database_id","subj":"3103","obj":"MESH:C000657245"},{"id":"A3104","pred":"tao:has_database_id","subj":"3104","obj":"MESH:C000657245"},{"id":"A3105","pred":"tao:has_database_id","subj":"3105","obj":"MESH:D008231"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In a case study conducted by Monneret et al. (301), compassionate administration of IL-7 to a patient with severe COVID-19 significantly improved total lymphocyte count and HLA-DR expression in circulating monocytes four days after administration of the first dose. The patient also showed a significant improvement in lung involvement and negative viral load. Another study conducted by Laterre et al. (302), who administered IL-7 to COVID-19 patients found that there was a significant improvement in the lymphocyte count after starting treatment, in addition, the patients did not show any change in TNF-α levels, IL-1β, and IL-12p70, which may indicate that IL-7 therapy may be safe for patients with severe inflammatory changes. Thus, the use of IL-7-based immunotherapy can be an important tool to be used in future clinical trials in patients with severe lymphopenia."}